سعر كاربالتا 30مجم 28 كبسولة 2024

Karbalta 30 mg capsules (duloxetine), pack of 28, Mash Premiere, Egypt.

• Major depressive disorder in adults.Population: AdultsDailyMed (U.S. National Library of Medicine)
• Generalised anxiety disorder in adults and paediatric patients 7 years and older.Population: Adults and children >= 7 yearsDailyMed (U.S. National Library of Medicine)
• Diabetic peripheral neuropathic pain and chronic musculoskeletal pain in adults; fibromyalgia in adults and paediatric patients 13 years and older.Population: Adults (fibromyalgia also >= 13 years)DailyMed (U.S. National Library of Medicine)

• Most common (>= 5% and at least twice placebo) - adults: nausea, dry mouth, somnolence, constipation, decreased appetite, hyperhidrosis; paediatric: decreased weight, decreased appetite, nausea, vomiting, fatigue, diarrhoea.International label, same formulation · DailyMed (U.S. National Library of Medicine)

• Use with an MAOI antidepressant or within 14 days of stopping one; starting duloxetine in patients treated with linezolid or intravenous methylene blue.International label, same formulation · DailyMed (U.S. National Library of Medicine)

• Boxed warning: increased risk of suicidal thoughts and behaviours in children, adolescents and young adults taking antidepressants; monitor for worsening and emergence of suicidality.International label, same formulation · DailyMed (U.S. National Library of Medicine)
• Hepatotoxicity (hepatic failure, sometimes fatal; avoid with substantial alcohol use or chronic liver disease); orthostatic hypotension, falls and syncope; serotonin syndrome; increased bleeding risk (especially with antiplatelets/anticoagulants); severe skin reactions incl. SJS; activation of mania/hypomania (screen for bipolar disorder); angle-closure glaucoma; seizures; blood pressure increases.International label, same formulation · DailyMed (U.S. National Library of Medicine)

• Potent CYP1A2 inhibitors (e.g. fluvoxamine)Avoid concomitant use (increased duloxetine exposure).DailyMed (U.S. National Library of Medicine)
• Potent CYP2D6 inhibitorsMay increase duloxetine concentrations.DailyMed (U.S. National Library of Medicine)
• CYP2D6 substratesDuloxetine is a moderate CYP2D6 inhibitor and may increase their concentrations.DailyMed (U.S. National Library of Medicine)

English text not available for this section.